This German Biotech Just Raised Millions to Transform Heart Disease Treatment

Jan de Vries · 2026-08-28

Let's talk about a fascinating development in European biotech. Revier Therapeutics, a startup based in Heidelberg, Germany, has officially launched with a $6.5 million seed round to take on cardiometabolic diseases. That's a big deal for patients and a significant signal for the European startup ecosystem. They're not just another research lab. They're targeting the underlying biology of conditions like heart failure and atherosclerosis. Think of it like this: instead of just treating symptoms, they're aiming to fix the engine, not just the check engine light. ### What Makes This Funding Round Unique The $6.5 million seed financing was led by the KHAN Technology Transfer Fund II. They didn't go it alone, though. They brought in High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors through Revier Invest Heidelberg. That's a powerful coalition of regional and specialized tech investors betting on deep science. It shows a real commitment to translating academic research into actual therapies. The business developer Daniel Stern, founder of Revier Invest Heidelberg, helped pull this regional coalition together. It's a model of how local stakeholders can fuel global innovation. ### The Science Behind the Startup So, what are they actually doing? Revier is pioneering a first-of-its-kind approach. They're selectively targeting a specific class of enzymes called class IIa histone deacetylases, or HDACs. These enzymes play a key role in severe diseases. Here's the breakthrough. Earlier HDAC inhibitors were like using a sledgehammer—they hit multiple targets and caused nasty side effects. Revier's orally available small molecules are designed to be a precision tool. - They aim to inhibit only the disease-causing activity. - They preserve healthy biological function. - They avoid the problematic "canonical" inhibition of other HDAC classes. Prof. Johannes Backs, MD, the scientific founder, put it well. He said their compounds are designed to be therapeutically effective while maintaining a beneficial safety profile. That's the holy grail in drug development. ### The Human Impact and Leadership Vision Prof. Eva van Rooij, PhD, the co-founder and CEO, framed the challenge perfectly. She pointed out that despite progress, millions of patients with HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease) still lack targeted treatments. > "We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology to deliver impactful and long-term solutions for patients," she said. Their mission is to translate the potential of class IIa HDAC inhibition into a pipeline of novel therapies. They want to rapidly advance their lead programs toward clinical trials. It's about creating long-term value for patients and the entire healthcare system. ### What's Next for Revier Therapeutics? The new capital has a clear job. It will support the development of their preclinical pipeline. That includes their lead program for HFpEF and their second program for ASCVD. The money will also help build out their operational, scientific, and clinical teams. Michael Hamacher, PhD, from KHAN Technology Transfer Fund II, summed up the investor confidence. He highlighted Revier's differentiated strategy to unlock HDAC biology's therapeutic promise while overcoming earlier limitations. He praised the exceptional leadership team and their deep scientific expertise. In short, this German biotech isn't just launching. It's positioning itself to potentially reshape the standard of care for cardiometabolic disorders. For professionals watching the European startup scene, especially in life sciences, this is one to keep a very close eye on. It represents the kind of deep-tech, patient-focused innovation that can define the next wave of European unicorns.